Effect of immunotherapy at any line of treatment on survival in Hispanic patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP).

ANDRES FELIPE CARDONA ZORRILLA; ALEJANDRO RUIZ-PATIÑO; OSCAR ARRIETA; CLAUDIO MARTIN; LUIS E. RAEZ; ZYANYA LUCIA ZATARAIN BARRÓN; FELICIANO BARRON BARRON; LUISA RICAURTE; MARIA BRAVO; LUIS MAS; LEONARDO ROJAS; LORENA LUPINACCI; FLORENCIA PERAZZO; CARMEN PUPARELLI; MANGLIO MIGUEL RIZZO; CHRISTIAN DIEGO ROLFO; JULY RODRIGUEZ; DIANA CAROLINA SOTELO RODRÍGUEZ; HERNAN CARRANZA; RAFAEL ROSELL

Boston

Congreso; ASCO meeting; 2019

ASCO

Background: To compare survival outcomes of patients with advanced or metastatic NSCLC who received immunotherapy at first, second or beyond versus matched patients receiving standard chemotherapy. Methods: A retrospective multicenter international cohort study of 296 patients with unresectable/ metastatic NSCLC treated with immunotherapy either as first, second, third or fourth line was conducted. A matched comparison with a historical cohort of first line chemotherapy was conducted. Results: Median age was 64 years (Range 34-90) and 40.2% were female patients. 91.2% of patients had an ECOG performance score ≤ 1. Immunotherapy as first line was given to 39 patients (13.7%), second line to 140 (48.8%), and as third line and beyond to 108 (37.6%). Median overall survival was 12.7 months (95% CI 9.67-14 months) and progression-free survival was 4.27 months (95% CI 3.97-5.0). Factors associated with increased survival included treatment as first-line (p < 0.001), type of response (p < 0.001) and PD-L1 status (p = 0.0039). Compared to the historical cohort, immunotherapy proved to be superior in terms of OS (p = 0.05) but not PFS (p = 0.2). Conclusions: Patients who receive immune checkpoint inhibitors as part of their treatment for NSCLC have better OS compared with matched patients treated with standard chemotherapy, regardless treatment line.